Egypt runs tests on AstraZeneca anti-Omicron drug before permitting its use

Official website of AstraZeneca

CAIRO – 21 December 2021: Chairman of AstraZeneca Egypt Hatem al-Werdany stated in a phone-in with TV host Amr Adib that Egypt’s Ministry of Health and Population is running tests on the anti-COVID-19 drug devised by the company to treat the omicron variant before it is offered in the Egyptian market.

Werdany pointed out that AstraZeneca prepares to supply 2.5 billion doses – worldwide – of the new drug, which has the form of an injection whose effect lasts between six months and a year.

In a similar context, the Egyptian Drug Authority (EDA) announced in November the start of clinical trials for the first Egyptian-made coronavirus vaccine Covi Vacc.

Egypt has received doses from the vaccines of Pfizer, Johnson & Johnson, Moderna, AstraZeneca, Sinovac, Sinopharm, Sputnik V. This is in addition to the raw material for the production of Sinovac/VACSERA vaccine doses.

Egypt has vaccinated almost 40 million people against coronavirus since the start of its vaccination campaign, Health Ministry Spokesman Hossam Abdel Ghaffar told media earlier.

Egypt Today

التعليقات

أخبار ذات صلة

صفحتنا على فيسبوك

آخر التغريدات